Diagnostic and prognostic value of miR-200 family in breast cancer: A meta-analysis and systematic review

• Published in: Cancer epidemiology 2022-04, Vol.77, p.102097-102097, Article 102097
• Main Authors: Thi Chung Duong, Thuy, Nguyen, Thu Huynh Ngoc, Thi Ngoc Nguyen, Thanh, Huynh, Luan Huu, Ngo, Hoang Phan, Thi Nguyen, Hue
• Format: Article
• Language: English
• Subjects: Accuracy; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Breast cancer; Breast carcinoma; Breast Neoplasms - diagnosis; Breast Neoplasms - genetics; Cancer; Confidence intervals; Diagnosis; Diagnostic systems; Epidemiology; ErbB-2 protein; Female; Heterogeneity; Humans; Malignancy; Medical diagnosis; Medical prognosis; Meta-analysis; Metastases; Methods; MicroRNAs; MicroRNAs - genetics; MiR-200 family; miRNA; Prognosis; Ribonucleic acid; RNA; Sensitivity; Subgroups; Systematic review; Tumors
• ISSN: 1877-7821; 1877-783X
• DOI: 10.1016/j.canep.2022.102097

Breast cancer (BC) is the most common cancer for women all over the world. Great interests have been paid to discover accurate and noninvasive methods for breast cancer diagnosis and prognosis. Although the diagnostic and prognostic value of microRNA-200 (miRNA- 200, miR-200) family has been revealed in many studies, the results were inconsistent. Thus, this meta-analysis aims to assess the overall value of miRNA-200 family in breast cancer diagnosis and prognosis. Relevant studies were searched from the following databases: PubMed, PMC, EMBASE, and ScienceDirect using key words: ("miRNA-200 family" or "miR-141" or "miR-200a" or "miR-200b" or "miR-200c" or "miR-429") and (“HER2” or “Luminal A” or “Luminal B” or “TNBC”) and ("breast cancers" or "breast carcinoma" or "breast malignancy" or "breast tumor"). The sensitivity, specificity, AUC were then calculated to estimate the diagnostic accuracy of the miR-200 family. As for the prognostic value of the miR-200 family, the pooled hazard ratio (HR) was assessed. Heterogeneity among individual studies was also examined by subgroup analyses. A total of 24 articles were included in the meta-analysis. The diagnostic value of miR-200s in BC was presented by the pooled sensitivity was 0.86 (95% CI: 0.83-0.88); the pooled specificity was 0.82 (95% CI: 0.72-0.89); the pooled AUC was 0.931 (95% CI: 0.919-0.942). Besides, expression of miR-200s in metastatic breast cancer has sensitivity, specificity and AUC of 0.70 (95%CI: 0.56-0.81), 0.72 (95%CI: 0.61-0.81), and 0.814 (95%CI: 0.741-0.903), respectively. The meta-analysis then revealed that high expression of miR-200 family corresponded to poor OS (HR: 1.63, 95% CI: 1.03-2.52), poor DFS (HR: 1.55, 95% CI: 0.95-2.56) in BC patients while downregulation of miRNA-200s corresponded to poor OS (HR= 0.84, 95%CI: 0.46-1.63) in TNBC patients and poor OS (HR=0.49; 95%CI: 0.27-0.88) in luminal BC patient. The MiR-200 family has high diagnostic accuracy and can be used as an important biomarker to prognosticate breast cancer. •This meta-analysis included 24 articles which provides an overall view about diagnostic and prognostic value of miR-200 family in breast cancer.•An accurate diagnostic marker of miR-200 family in breast cancer was investigated from 6 studies with 3101 cases and 409 controls. Besides, diagnostic value of miR-200 s in metastasis breast cancer was investigated from 5 articles with 330 cases and 534 controls.•A high expression of miR-200 family was associated w